SBRX14

SBRX14 is a plant-based drug candidate being developed by Stramsen Biotech, a Texas-based biopharmaceutical company, for the treatment of male hypogonadism and male infertility. The therapeutic is designed to stimulate androgen production and support the various stages of spermatogenesis, including sperm development and maturation. As part of Stramsen's SBRX series, the candidate is derived from a proprietary database of medicinal plants and represents a natural approach to addressing hormonal imbalances and reproductive dysfunction in men. It is currently in the early development stage as part of a broader pipeline of plant-derived therapeutics.